Generic Fosamax Users Must Give More Details In MDL

Law360, New York (December 19, 2013, 8:04 PM EST) -- A New York federal judge on Wednesday ordered plaintiffs in multidistrict litigation against Teva Pharmaceuticals USA Inc. to divulge when they had taken a generic version of the bone drug Fosamax, in order to back the claim that Teva's failure to update the drug's labeling had led to their jaw injuries.

The ruling came in response to Teva's motion for a more definite statement following U.S. District Judge John Keenan's August decision that all of the claims against Teva were preempted except so-called failure-to-update allegations....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.